Additionally, clinical trials have demonstrated that PD-1/PD-L1 blockade can provide a durable clinical response in specific tumor types and patient populations and may lead to long-term tumor non-progression after treatment discontinuation in some patients, thereby potentially enhancing overall survival 4, 5. The gene discussed is SNCA; the disease is neoplasm.